keyword
MENU ▼
Read by QxMD icon Read
search

beta-lactamase inhibitor

keyword
https://www.readbyqxmd.com/read/28483952/outcomes-with-ceftazidime-avibactam-in-patients-with-carbapenem-resistant-enterobacteriaceae-cre-infections-a-multi-center-study
#1
Madeline King, Emily Heil, Safia Kuriakose, Tiffany Bias, Vanthida Huang, Claudine El-Beyrouty, Dorothy McCoy, Jon Hiles, Lynette Richards, Julianne Gardner, Nicole Harrington, Kenneth Biason, Jason Gallagher
Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe a retrospective chart review whereby 60 patients received ceftazidime-avibactam for a CRE infection. In hospital mortality was 32%, 53% of patients had microbiological cure, and 65% had clinical success. In this severely ill population with CRE infections, ceftazidime-avibactam was an appropriate option.
May 8, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28465626/synthesis-and-biological-evaluation-of-indole-core-based-derivatives-with-potent-antibacterial-activity-against-resistant-bacterial-pathogens
#2
Wei Hong, Jingyang Li, Zhe Chang, Xiaoli Tan, Hao Yang, Yifan Ouyang, Yanhui Yang, Sargit Kaur, Ian C Paterson, Yun Fong Ngeow, Hao Wang
The emergence of drug resistance in bacterial pathogens is a growing clinical problem that poses difficult challenges in patient management. To exacerbate this problem, there is currently a serious lack of antibacterial agents that are designed to target extremely drug-resistant bacterial strains. Here we describe the design, synthesis and antibacterial testing of a series of 40 novel indole core derivatives, which are predicated by molecular modeling to be potential glycosyltransferase inhibitors. Twenty of these derivatives were found to show in vitro inhibition of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus...
May 3, 2017: Journal of Antibiotics
https://www.readbyqxmd.com/read/28377310/risk-factors-for-extended-spectrum-beta-lactamase-producing-escherichia-coli-urinary-tract-infection-in-the-community-in-denmark-a-case-control-study
#3
Mette Søgaard, Uffe Heide-Jørgensen, Jan P Vandenbroucke, Henrik C Schønheyder, Christina Mje Vandenbroucke-Grauls
OBJECTIVE: To verify the role of proton pump inhibitors (PPI) and nitrofurantoin, which have appeared as novel risk factors for carriage of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli, as risk factors for ESBL E.coli urinary tract infection (UTI). We included known risk factors to ascertain whether our findings are comparable with previous studies. METHODS: Population-based case-control study including 339 cases with community-onset ESBL E...
April 1, 2017: Clinical Microbiology and Infection
https://www.readbyqxmd.com/read/28367020/comparison-of-four-phenotypic-methods-for-detection-of-metallo-%C3%AE-lactamase-producing-gram-negative-bacteria-in-rural-teaching-hospital
#4
Chinjal A Panchal, Sweta Sunil Oza, Sanjay J Mehta
CONTEXT: Metallo-β-lactamase (MBL)-producing bacteria lead to resistance to carbapenem an antibiotic that used as the last resort for treatment of multidrug-resistant bacteria, extended spectrum beta-lactamases, and AmpC β-lactamase-producing Gram-negative bacteria (GNB). The emergence of MBL-producing GNB is challenge to microbiology laboratories because there are no standardized guidelines available to detect them. The aim of this study was to compare four phenotypic methods to detect MBL production in GNB and to determine antibiotic sensitivity of MBL-producing isolates...
April 2017: Journal of Laboratory Physicians
https://www.readbyqxmd.com/read/28343258/variation-of-antibiotic-consumption-and-its-correlated-factors-in-turkey
#5
Ayfer Sahin, Ahmet Akici, Volkan Aydin, Bahar Melik, Mesil Aksoy, Ali Alkan
BACKGROUND: Presentation of antibiotic utilization data by reliable and comparable analyses constitutes an important way of ensuring rational use of antibiotics. This study aimed to evaluate antibiotic consumption (AC) of Turkey by each city/region and to investigate any association of such consumption with socio-economic factors. METHOD: For 81 provinces and 12 regions in Turkey, AC data from IMS (Intercontinental Medical Statistics) in 2011 was analyzed in accordance with "ATC/DDD, DID" (Anatomical Therapeutic Chemical/Defined Daily Doses, DID = DDD/1000 inhabitants/day) methodology supported by World Health Organization...
March 25, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28338347/ceftazidime-avibactam-novel-antimicrobial-combination-for-the-treatment-of-complicated-urinary-tract-infections
#6
Jakhongir F Alidjanov, Moritz Fritzenwanker, Ivan Hoffman, Florian M Wagenlehner
Ceftazidime-avibactam is a combination of a third-generation cephalosporin and a novel non-beta-lactam beta-lactamase inhibitor. This combination was recently recommended for the treatment of complicated urinary tract infections, including acute pyelonephritis, in adults with limited or no alternative treatment options. The current review is aimed to determine activity, efficacy and safety of ceftazidime-avibactam in the treatment of patients with complicated urinary tract infections.
March 24, 2017: Future Microbiology
https://www.readbyqxmd.com/read/28303449/novel-beta-lactamase-inhibitors-unlocking-their-potential-in-therapy
#7
REVIEW
Darren Wong, David van Duin
Carbapenem-resistant Enterobacteriaceae are amongst the most feared pathogens due to severely limited treatment options. In response to this threat, three novel β-lactamase inhibitors have been developed in an attempt to reinvigorate and sustain our current antimicrobial therapies. Avibactam, vaborbactam, and relebactam are inhibitor agents with high affinity to Ambler class A and C β-lactamases and favorable outcomes in current clinical trials. However, although they do possess key similarities, these agents have unique differences which may have important clinical implications...
April 2017: Drugs
https://www.readbyqxmd.com/read/28299853/the-effect-of-a-beta-lactamase-inhibitor-peptide-on-bacterial-membrane-structure-and-integrity-a-comparative-study
#8
Begum Alaybeyoglu, Bilge Gedik Uluocak, Berna Sariyar Akbulut, Elif Ozkirimli
Co-administration of beta-lactam antibiotics and beta-lactamase inhibitors has been a favored treatment strategy against beta-lactamase-mediated bacterial antibiotic resistance, but the emergence of beta-lactamases resistant to current inhibitors necessitates the discovery of novel non-beta-lactam inhibitors. Peptides derived from the Ala46-Tyr51 region of the beta-lactamase inhibitor protein are considered as potent inhibitors of beta-lactamase; unfortunately, peptide delivery into the cell limits their potential...
May 2017: Journal of Peptide Science: An Official Publication of the European Peptide Society
https://www.readbyqxmd.com/read/28289035/wck-5107-zidebactam-wck-5153-novel-inhibitors-of-pbp2-showing-potent-%C3%AE-lactam-enhancer-activity-against-pseudomonas-aeruginosa-including-multidrug-resistant-metallo-%C3%AE-lactamase-producing-high-risk-clones
#9
Bartolome Moya, Isabel M Barcelo, Sachin Bhagwat, Mahesh Patel, German Bou, Krisztina M Papp-Wallace, Robert A Bonomo, Antonio Oliver
Zidebactam and WCK 5153 are novel β-lactam enhancers that are bicyclo-acyl hydrazides (BCH), derivatives of diazabicyclooctane (DBO) scaffold, targeted for the treatment of serious infections caused by highly drug-resistant Gram-negative pathogens. In this report, we determined the PBP inhibition profiles and the antimicrobial activity of zidebactam and WCK 5153 against P. aeruginosa, including multidrug-resistant (MDR) metallo-β-lactamase (MBL)-producing high-risk clones. MICs and time-kill assays were conducted for zidebactam, WCK 5153 and antipseudomonal β-lactams using wild-type PAO1 strain, MexAB-OprM-hyperproducing (mexR), porin deficient (oprD) and AmpC-hyperproducing (dacB) derivatives of PAO1 and MBL-expressing clinical strains, ST175 (blaVIM-2) and ST111 (blaVIM-1)...
March 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28247443/acute-kidney-injury-in-patients-treated-with-iv-beta-lactam-beta-lactamase-inhibitor-combinations
#10
W Cliff Rutter, David S Burgess
STUDY OBJECTIVE: Increased acute kidney injury (AKI) incidence has been reported in patients receiving piperacillin-tazobactam (PTZ) therapy compared with other β-lactams. The authors sought to determine if the addition of β-lactamase inhibitors impacts AKI incidence by comparing patients treated with PTZ or ampicillin-sulbactam (SAM). DESIGN: Retrospective cohort study. SETTING: Large academic tertiary care hospital. PATIENTS: Overall, 2448 patients received PTZ (n=1836) or SAM (n=612) for at least 48 hours between September 1, 2007, and September 30, 2015...
May 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28244482/the-microbial-etiology-and-antimicrobial-susceptibility-of-bloodstream-infections-in-patients-with-cancer-at-a-private-tertiary-care-hospital-in-mumbai-india
#11
T Singhal, S Shah, R Naik
BACKGROUND: Knowledge of the etiology and antimicrobial susceptibility of blood stream infections in patients with cancer is crucial to design empirical therapy regimes. METHODS: This is a prospective observational study at a tertiary care private hospital in Mumbai, India from Nov 2009 - Dec 2014. RESULTS: A total of 62 episodes of blood stream infections in 57 patients with cancer were recorded during the study period. Analysis was limited to 52 isolates from 49 episodes in 45 patients...
July 2016: Indian Journal of Cancer
https://www.readbyqxmd.com/read/28193660/antimicrobial-resistance-of-escherichia-coli-urinary-isolates-in-the-veterans-affairs-health-care-system
#12
Haley J Morrill, Jacob B Morton, Aisling R Caffrey, Lan Jiang, David Dosa, Leonard A Mermel, Kerry L LaPlante
We reviewed data for almost 300,000 clinical Escherichia coli urinary isolates (collected in 2009 through 2013) from 127 inpatient and outpatient facilities, to assess antibiotic resistance among Veterans Affairs health care system patients using Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention National Healthcare Safety Network definitions or guidance. Rates of resistance to amoxicillin or ampicillin/β-lactamase inhibitors were approximately 40% and rates of resistance to fluoroquinolones and trimethoprim-sulfamethoxazole approached 30%...
May 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28164610/an-investigation-of-the-frequency-of-upper-respiratory-tract-infection-pathogens-and-their-antibiotic-patterns-in-tonsils-and-adenoids-of-adenotonsillectomy-patients
#13
Yasar Nakipoglu, Gulsen Gunel, Deniz Kanliada, Levent Aydemir, Nezahat Gurler, Bulent Gurler
BACKGROUND: We aimed to investigate the potentially pathogenic bacteria of upper respiratory tract infections (URTIs) and their susceptibilities to different antibiotics. METHODS: Two-hundred adenoid and tonsil specimens from 100 patients who had undergone adenotonsillectomy were obtained and analyzed bacteriologically. Identification of the pathogens was made by conventional or commercial identification systems and antibiotic susceptibility tests were carried out by disk diffusion method...
August 1, 2016: Clinical Laboratory
https://www.readbyqxmd.com/read/28157141/icu-acquisition-rate-risk-factors-and-clinical-significance-of-digestive-tract-colonization-with-extended-spectrum-beta-lactamase-producing-enterobacteriaceae-a-systematic-review-and-meta-analysis
#14
Marios Detsis, Styliani Karanika, Eleftherios Mylonakis
OBJECTIVE: To evaluate the acquisition rate, identify risk factors, and estimate the risk for subsequent infection, associated with the colonization of the digestive tract with extended-spectrum beta-lactamase-producing Enterobacteriaceae during ICU-hospitalization. DATA SOURCES: PubMed, EMBASE, and reference lists of all eligible articles. STUDY SELECTION: Included studies provided data on ICU-acquired colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae in previously noncolonized and noninfected patients and used the double disk synergy test for extended-spectrum beta-lactamase-producing Enterobacteriaceae phenotypic confirmation...
April 2017: Critical Care Medicine
https://www.readbyqxmd.com/read/28139430/prevalence-of-mcr-1-in-escherichia-coli-and-klebsiella-pneumoniae-recovered-from-bloodstream-infections-in-china-a-multicentre-longitudinal-study
#15
Jingjing Quan, Xi Li, Yan Chen, Yan Jiang, Zhihui Zhou, Huichuan Zhang, Lu Sun, Zhi Ruan, Ye Feng, Murat Akova, Yunsong Yu
BACKGROUND: Polymyxin antibiotics are used as last-resort therapies to treat infections caused by multidrug-resistant Gram-negative bacteria. The plasmid-mediated colistin resistance determinant MCR-1 has been identified in Enterobacteriaceae in China. We did this study to investigate the prevalence of the mcr-1 gene in clinical isolates from patients with bloodstream infections in China. METHODS: Clinical isolates of Escherichia coli and Klebsiella pneumoniae were collected from patients with bloodstream infections at 28 hospitals in China, then screened for colistin resistance by broth microdilution and for the presence of the mcr-1 gene by PCR amplification...
April 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28129568/structure-based-virtual-screening-to-identify-the-beta-lactamase-ctx-m-9-inhibitors-an-in-silico-effort-to-overcome-antibiotic-resistance-in-e-coli
#16
Kambiz Davari, Jamileh Nowroozi, Farzaneh Hosseini, Abbas Akhavan Sepahy, Sako Mirzaie
Recently, the quick spreads of broad-spectrum beta-lactams antibiotic resistance in pathogenic strains of bacteria have become a major global health problem. These new emerging resistances cause ineffectiveness of antibiotics and increasing the severity of diseases and treatment costs. Among different and diverse resistance targets, we chose a class A beta lactamase, CTX-M-9, with the aim of identifying new chemical entities to be used for further rational drug design. Based on this purpose, a set of 5000 molecules from the Zinc database have been screened by docking experiments using AutoDock Vina software...
January 22, 2017: Computational Biology and Chemistry
https://www.readbyqxmd.com/read/28127422/risk-factors-for-relapse-or-persistence-of-bacteraemia-caused-by-enterobacter-spp-a-case-control-study
#17
Patrick N A Harris, Anna M Peri, Anita M Pelecanos, Carly M Hughes, David L Paterson, John K Ferguson
BACKGROUND: Enterobacter spp. possess chromosomal AmpC beta-lactamases that may be expressed at high levels. Previous studies have demonstrated a risk of relapsed bacteraemia following therapy with third generation cephalosporins (3GCs). What additional factors predict microbiological failure in Enterobacter bacteraemia is unclear. We aimed to determine factors associated with microbiological failure in Enterobacter bacteraemia. METHODS: We retrospectively identified cases of bacteraemia caused by Enterobacter spp...
2017: Antimicrobial Resistance and Infection Control
https://www.readbyqxmd.com/read/28126276/captopril-enalapril-inhibit-promiscuous-esterase-activity-of-carbonic-anhydrase-at-micromolar-concentrations-an-in%C3%A2-vitro-study
#18
Sajjad Esmaeili, Mohammad Reza Ashrafi-Kooshk, Hadi Adibi, Reza Khodarahmi
The inhibitory activity of captopril, a thiol-containing competitive inhibitor of the angiotensin-converting enzyme, ACE, against esterase activity of carbonic anhydrase, CA was investigated. This small molecule, as well as enalapril, was selected in order to represents both thiol and carboxylate, as two well-known metal binding functional groups of metalloprotein inhibitors. Since captopril, has also been observed to inhibit other metalloenzymes such as tyrosinase and metallo-beta lactamase through binding to the catalytic metal ions and regarding CA as a zinc-containing metallo-enzyme, in the current study, we set out to determine whether captopril/enalapril inhibit CA esterase activity of the purified human CA II or not? Then, we revealed the inhibitors' potencies (IC50, Ki and Kdiss values) and also mode of inhibition...
March 1, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/27951476/a-nitrocefin-based-amperometric-assay-for-the-rapid-quantification-of-extended-spectrum-%C3%AE-lactamase-producing-escherichia-coli-in-wastewaters
#19
Benoît Chantemesse, Laetitia Betelli, Sébastien Solanas, Fabienne Vienney, Loïc Bollache, Alain Hartmann, Murielle Rochelet
A sensitive and inexpensive amperometric assay based on the electrochemical detection of the β-lactamase activity using the nitrocefin as substrate was developed for the rapid and quantitative detection of extended spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in urban wastewaters. The specific detection of ESBL-EC was achieved by culturing the filtered sample in a medium containing the cefotaxime supplemented or not with the potassium clavulanate inhibitor. This step was followed by the incubation of each subculture filtrate with the nitrocefin substrate which hydrolysis was monitored by amperometry using disposable carbon screen-printed sensors...
February 1, 2017: Water Research
https://www.readbyqxmd.com/read/27943428/synthesis-of-2-mercaptoacetyl-l-2-14-c-tryptophan-as-a-selective-metallo-%C3%AE-lactamase-inhibitor-via-2-14-c-indole-based-on-chiral-pool-strategy
#20
Gholamhossein Shirvani, Abbas Shockravi, Mohsen Amini, Nader Saemian
Metallo-beta-lactamase enzymes make bacteria resistant to a broad range of commonly used beta-lactam antibiotics. Several thiol derivatives of L-amino acids have been shown their inhibitory effects against the metallo-β-lactamase IMP-1. In this study, (2-mercaptoacetyl)-L-tryptophan as a new inhibitor of metallo-β-lactamases labeled with carbon-14 in the 2-position of the indole ring was prepared from [2-(14) C]indole as a key synthetic intermediate based on chiral pool strategy. The overall synthesis was performed in 10 steps with the overall radiochemical yield 3...
December 12, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
keyword
keyword
112982
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"